pharmaceutical investing Zealand Pharma Doses First Patient in Phase 3 Trial with Dasiglucagon for Treatment of Congenital Hyperinsulinism
pharmaceutical investing Zealand Pharma achieves primary and key secondary endpoints in pivotal Phase 3 trial with dasiglucagon for severe hypoglycemia
Quebec Innovative Materials Corp. Announces U.S. Affiliate Orvian Receives Minnesota DNR Registration for Exploratory Boring
